Poor Prognosis of Pneumococcal Co-Infection in Hospitalized Patients with COVID-19: A Propensity Score-Matched Analysis.

IF 2.9 Q2 INFECTIOUS DISEASES

Infection and Chemotherapy Pub Date : 2025-03-01 DOI:10.3947/ic.2024.0130

Soyoon Hwang, Eunkyung Nam, Shin-Woo Kim, Hyun-Ha Chang, Yoonjung Kim, Sohyun Bae, Nan Young Lee, Yu Kyung Kim, Ji Sun Kim, Han Wook Park, Joon Gyu Bae, Juhwan Jeong, Ki Tae Kwon

{"title":"Poor Prognosis of Pneumococcal Co-Infection in Hospitalized Patients with COVID-19: A Propensity Score-Matched Analysis.","authors":"Soyoon Hwang, Eunkyung Nam, Shin-Woo Kim, Hyun-Ha Chang, Yoonjung Kim, Sohyun Bae, Nan Young Lee, Yu Kyung Kim, Ji Sun Kim, Han Wook Park, Joon Gyu Bae, Juhwan Jeong, Ki Tae Kwon","doi":"10.3947/ic.2024.0130","DOIUrl":null,"url":null,"abstract":"The impact of Streptococcus pneumoniae coinfection on coronavirus disease 2019 (COVID-19) prognosis remains uncertain. We conducted a retrospective analysis of patients hospitalized with COVID-19 who underwent a pneumococcal urinary antigen (PUA) test to assess its clinical utility. Results showed that PUA-positive patients required more oxygen support, high-flow nasal cannula, and dexamethasone compared to PUA-negative patients. Furthermore, the significantly higher incidence of a National Early Warning Score ≥5 in the PUA-positive group (P<0.001) suggests that a positive PUA test is associated with a severe disease course. However, no significant difference in mortality was observed between the two groups, and antibiotics were used in almost all patients (96.2%). While the PUA test may help guide antibiotic use in COVID-19 patients, its interpretation should be approached with caution.","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"57 1","pages":"172-178"},"PeriodicalIF":2.9000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972905/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3947/ic.2024.0130","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

The impact of Streptococcus pneumoniae coinfection on coronavirus disease 2019 (COVID-19) prognosis remains uncertain. We conducted a retrospective analysis of patients hospitalized with COVID-19 who underwent a pneumococcal urinary antigen (PUA) test to assess its clinical utility. Results showed that PUA-positive patients required more oxygen support, high-flow nasal cannula, and dexamethasone compared to PUA-negative patients. Furthermore, the significantly higher incidence of a National Early Warning Score ≥5 in the PUA-positive group (P<0.001) suggests that a positive PUA test is associated with a severe disease course. However, no significant difference in mortality was observed between the two groups, and antibiotics were used in almost all patients (96.2%). While the PUA test may help guide antibiotic use in COVID-19 patients, its interpretation should be approached with caution.

查看原文本刊更多论文

COVID-19住院患者肺炎球菌合并感染的不良预后：倾向评分匹配分析

肺炎链球菌合并感染对2019冠状病毒病（COVID-19）预后的影响尚不确定。我们对接受肺炎球菌尿抗原（PUA）检测的COVID-19住院患者进行了回顾性分析，以评估其临床效用。结果显示，与pua阴性患者相比，pua阳性患者需要更多的氧支持、高流量鼻插管和地塞米松。此外，pua阳性组国家预警评分≥5的发生率显著高于对照组(P

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊